Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

Technology appraisal guidance
Reference number: TA127
Published: 22 August 2007
Last updated: 21 May 2024

Multiple sclerosis - natalizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive

Multiple sclerosis - natalizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive

Multiple sclerosis - natalizumab: Appendix B - proposal paper presented to the Institute's Guidance Executive
02 May 2013
(749.78 Kb 38 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 30 April 2013